The pharmaceutical giants and academics are working to assess challenges and seek opportunities that could influence Becker Muscular Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
DelveInsight’s “Becker Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Becker Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Becker Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Becker Muscular Dystrophy: An Overview
Becker Muscular Dystrophy (BMD) is an inherited muscle structure disorder resulting in progressive deterioration of limbs and cardiac and skeletal muscle deterioration. However, the involuntary muscles are not affected. BMD is a milder version of Duchenne Muscular Dystrophy (DMD). BMD usually begins in teens or early adulthood, and the course is slower and far less predictable than that of DMD.
Early symptoms of BMD are cramps after exercising, and later in life, the person begins to experience problems while walking quickly or running. Other noticeable symptoms besides weakness are falling, feeling “worn out,” and changes in the skeletal system. Muscle weakness often affects the legs and pelvis and slowly gets worse. Few affected individuals even have learning problems, but these cases are typically minor.
Becker Muscular Dystrophy Market Key Facts
According to the Genetic and Rare Diseases Information Center, the prevalence of Becker Muscular Dystrophy is estimated to be between 17–27 cases per million people. This means that at a given time, about one in 37,000 to one in 59,000 people are living with Becker Muscular Dystrophy.
According to the Centers for Disease Control and Prevention (CDC), the estimated prevalence of Duchenne and Becker muscular dystrophy (DBecker Muscular Dystrophy) was one in every 7,250 males aged 5–24 years. However, the prevalence of DMD was found to be three times higher than the prevalence of Becker Muscular Dystrophy.
Becker Muscular Dystrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Becker Muscular Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Becker Muscular Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Becker Muscular Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Becker Muscular Dystrophy Epidemiology, Segmented as –
Prevalent Cases of BMD in the 7MM (2019–2032)
Age-specific Prevalent Cases of BMD in the 7MM (2019–2032)
Diagnosed and Treatable Cases of BMD in the 7MM (2019–2032)
Becker Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Becker Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Becker Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Becker Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Becker Muscular Dystrophy Market Will Evolve and Grow by 2032 @
Becker Muscular Dystrophy Therapeutics Analysis
Several major pharma and biotech players are involved in developing Becker Muscular Dystrophy therapies. The launch of emerging therapies is anticipated to impact the Becker Muscular Dystrophy market significantly. Moreover, a better understanding of Becker Muscular Dystrophy pathogenesis will also contribute to developing novel therapeutics for Becker Muscular Dystrophy.
Currently, Italfarmaco is leading the therapeutics market with its Becker Muscular Dystrophy drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Becker Muscular Dystrophy Therapeutics Market Include:
And Many Others
Becker Muscular Dystrophy Emerging and Marketed Drugs Covered in the Report Include:
EDG 5506 : Edgewise Therapeutics
Epicatechi: Epirium Bio
Translarna: PTC Therapeutics
Vamorolone: ReveraGen biopharma
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Becker Muscular Dystrophy Competitive Intelligence Analysis
4. Becker Muscular Dystrophy Market Overview at a Glance
5. Becker Muscular Dystrophy Disease Background and Overview
6. Becker Muscular Dystrophy Patient Journey
7. Becker Muscular Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Becker Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Becker Muscular Dystrophy Unmet Needs
10. Key Endpoints of Becker Muscular Dystrophy Treatment
11. Becker Muscular Dystrophy Marketed Products
12. Becker Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Becker Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Becker Muscular Dystrophy Market Outlook (In US, EU5, and Japan)
16. Becker Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Becker Muscular Dystrophy Market
18. Becker Muscular Dystrophy Market Drivers
19. Becker Muscular Dystrophy Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States